EDP Biotech Preparing to Discuss Its Colon Cancer Dx with FDA

The company plans to begin a clinical trial in the hopes of getting its ColoMarker test cleared by the FDA as a screening tool for colorectal cancer in about three years.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.